Cholangiocarcinoma

The PURITY trial compares giving a three-drug chemotherapy combination before surgery with going straight to surgery in people with biliary tract cancer that can be removed but has a high risk of returning. Participants are adults under 75 with confirmed, non-metastatic biliary t…

This phase 2 trial tests whether a combination of three treatments can shrink inoperable intrahepatic cholangiocarcinoma (a type of bile duct cancer) enough to allow surgical removal. The approach delivers chemotherapy directly into the liver's blood supply (HAIC) along with the …

This early-phase study tests a personalized mRNA cancer vaccine (XH001) given alongside standard treatment after surgery for people with high-risk solid tumors (bile duct, gallbladder, pancreatic, liver, or stomach cancer). The main goals are to check safety and see if the vaccin…

Researchers are testing a combination treatment for intrahepatic cholangiocarcinoma, a type of liver cancer that cannot be removed by surgery. The study gives participants Y-90 radioembolization, which delivers radiation directly to liver tumors, followed by six cycles of the che…

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This study tests a combination of two immunotherapy drugs (iparomlimab and toripalimab) plus bevacizumab and chemotherapy as a first treatment for advanced biliary tract cancer. It involves 32 adults aged 18-75 who have not had prior treatment for their advanced cancer. The goal …

This study is for people with liver cancer that cannot be removed by surgery. Researchers want to find the exact amount of radiation needed to completely destroy the tumor using a special procedure called Y90 radioembolization. About 30 adults will take part to help improve treat…

This study tests whether adding the drug zanidatamab to standard chemotherapy (with or without an immunotherapy) can help people with advanced HER2-positive bile duct cancer live longer without their cancer growing. About 286 adults with inoperable or metastatic bile duct cancer …

This early-phase trial tests whether injecting a medical glue (Histoacryl®) into the pancreas during Whipple surgery can strengthen the connection between the pancreas and intestine and prevent dangerous leaks. The study involves 30 patients with soft pancreases and narrow ducts,…

This phase II trial is testing whether alternating standard chemotherapy and immunotherapy with a targeted drug called pemigatinib can help people with advanced biliary tract cancers that have FGFR2 alterations. The study includes adults with cancer that cannot be removed by surg…

This trial tests whether adding radiofrequency ablation to standard chemotherapy and bile duct stenting helps patients with inoperable bile duct cancer. Radiofrequency ablation uses a catheter to deliver heat that destroys tumor tissue blocking the bile duct. Researchers compare …

This phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …

This study tests an experimental drug called TNG462 for people with advanced solid tumors that have a specific genetic deletion (MTAP). The drug is taken by mouth and aims to slow or stop tumor growth. The trial has two parts: first, finding the safest dose, and then testing that…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …

This study tests whether adding an immune-boosting drug (PDS01ADC) to standard chemotherapy delivered directly to the liver can help people with colorectal, bile duct, or adrenal cancer that has spread to the liver. About 70 adults will receive the drug combination along with a s…

This study tests whether combining two drugs (pemigatinib and durvalumab) can shrink or control advanced bile duct cancer that has a specific FGFR2 gene change. About 38 adults whose cancer has not responded to prior treatment will receive daily pills and an IV infusion every 3 w…

This Phase 2 trial is testing two doses (20 mg and 16 mg) of the oral drug futibatinib in 120 people with advanced bile duct cancer that has specific FGFR2 gene changes. Participants must have already tried standard chemotherapy. The study aims to see which dose works better at s…

This study tests a drug called tivozanib in people with bile duct cancer that cannot be removed by surgery and has already been treated with chemotherapy. The goal is to find the safest dose and see if the drug can shrink tumors or slow the cancer. Participants take tivozanib by …

This study tests a new drug called ivonescimab against standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has worsened after initial treatment. About 72 participants who were in the SAFIR-ABC10 trial will be randomly assigned to receive either ivonescim…

This early-phase trial is testing a new drug called DB-1303/BNT323 in people with advanced HER2-positive solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. About 800 participants will take part ac…

This phase II trial is testing whether combining pemigatinib—a drug that targets FGFR2 mutations—with an immunotherapy drug (a PD-1 inhibitor) and possibly chemotherapy can help people with advanced bile duct cancer that has FGFR2 fusions or rearrangements. The study enrolls adul…

This trial is investigating whether giving a combination of chemotherapy and immunotherapy before surgery, and continuing immunotherapy after, can improve outcomes for people with a rare and aggressive type of bile duct cancer. Participants will be randomly assigned to receive ei…

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…

This early-stage study tests a new drug (177Lu-DOTA-SNA040) that delivers radiation directly to cancer cells with a specific marker (Claudin 18.2). It is for people with advanced stomach, pancreatic, or bile duct cancers that have worsened after standard treatment. The main goals…

This early-phase trial tests a new drug called AB801, which blocks a protein (AXL) that helps cancers grow and resist treatment. It is given alongside chemotherapy and immunotherapy to people with bile duct or pancreatic cancer that is either borderline resectable, locally advanc…

This trial tests a streamlined version of radioembolization, a treatment that delivers tiny radioactive beads directly to liver tumors. The standard procedure requires extra imaging beforehand to check for radiation leakage to the lungs, which can delay treatment. For patients wi…

This study tests whether combining three drugs—pemigatinib, atezolizumab, and bevacizumab—can help control advanced bile duct cancer that has a specific genetic change (FGFR2 fusion). About 25 adults whose cancer has not responded to other treatments will take part. The main goal…

This study compares standard chemotherapy (gemcitabine and oxaliplatin) alone versus the same drugs plus a liver-directed chemotherapy (HAI FUDR/dexamethasone) in people with bile duct cancer that has spread within the liver but cannot be removed surgically. About 164 adults with…

This trial tests whether phycocyanin, a natural protein from spirulina, can reduce liver injury and support recovery in adults having part of their liver removed due to intrahepatic cholangiocarcinoma. About 30 participants will take either phycocyanin or a placebo daily for thre…

This early-phase study tests a combination of two drugs (BMS-986504 and olaparib) in adults with advanced solid tumors that have lost a gene called MTAP. The main goal is to find safe doses and understand side effects. About 36 people will take part, and the study is currently re…

This study tests a drug called ivosidenib in people with a specific type of bile duct cancer (IDH1-mutated) that has been surgically removed. After standard chemotherapy, participants take ivosidenib daily to see if it helps keep the cancer from returning. The trial involves 40 a…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This early-phase trial tests a new type of cell therapy called TCR1188-ABC for people with certain advanced cancers (pancreatic, colorectal, lung, or bile duct) that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune cells, engineering them t…

This early-stage trial tests a technique called PIPAC, which turns chemotherapy into a fine mist and sprays it directly into the abdomen during a keyhole surgery. The goal is to see if this method is safe and reduces side effects for people with biliary tract cancer that has spre…

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This study is tracking 100 adults with a rare and aggressive bile duct cancer that has a specific IDH1 gene mutation. Participants will take the targeted drug ivosidenib, which was recently approved in Europe. Researchers will monitor how long the cancer stays under control, over…

This study tests whether adding an experimental drug (D07001) to standard chemotherapy (capecitabine) helps people with advanced bile duct cancer live longer. About 195 adults whose cancer has not responded to earlier treatments will receive either D07001 or a placebo, plus capec…

This study tests a drug called FORE8394 (plixorafenib) in people aged 10 and older whose cancers have specific BRAF gene changes. The goal is to see if the drug can shrink tumors or slow their growth. About 254 participants with advanced solid tumors or brain tumors will take the…

This early-phase trial tests a new drug called TPD3310 in 112 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive weekly injections over 28-day cycl…

This study tests whether combining chemotherapy (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab) and a targeted radiation treatment (Yttrium-90 microspheres) can shrink tumors in people with locally advanced bile duct cancer that cannot be removed by surgery. T…

This study tests a combination of two drugs, GNS561 and trametinib, in people with advanced bile duct cancer that has a specific genetic change (KRAS mutation) and has not responded to standard first-line therapy. The trial has two phases: first to find the safest dose, then to s…

This study tests a new approach for people with advanced liver cancer that cannot be surgically removed. Participants receive radiation followed by an injection of their own specially trained immune cells (dendritic cells), a pneumonia vaccine to boost immunity, and immunotherapy…

This early-stage trial is testing a new drug called PLT012 in adults with advanced solid tumors that have not responded to standard treatments. PLT012 is an antibody that targets a protein called CD36 found on some cancer cells. The main goals are to find safe doses and to see if…

This study tests a new drug called ALE.P03 in adults with advanced or metastatic solid tumors that have a specific protein (Claudin-1) on their surface. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial has two phases: …

This study tests whether adding a targeted, tumor-destroying treatment (like focused radiation or heat ablation) can help people with certain gastrointestinal cancers—such as colorectal, small bowel, or pancreatic cancer—continue their current systemic therapy longer when only a …

This phase 3 trial tests a new drug called nanvuranlat in 480 adults with advanced biliary tract cancer that has worsened after prior treatment. Participants receive either nanvuranlat or one of several standard treatments. The main goal is to see if nanvuranlat helps people live…

This early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body proce…

This early-stage study is testing a new treatment called SynKIR-110 for people with advanced ovarian cancer, bile duct cancer, or mesothelioma that has spread or come back. The treatment involves taking a patient's own immune cells, engineering them in a lab to better recognize a…

This study is testing whether giving chemotherapy (capecitabine or S-1) together with radiation after surgery can help prevent bile duct and gallbladder cancers from coming back. It includes 92 patients whose cancers had high-risk features, like positive lymph nodes or narrow sur…

This study tests a combination of two drugs (apatinib and adebrelimab) plus chemotherapy (GEMOX) as a first treatment for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer that cannot be removed by surgery. The goal is to see if this mix shrinks tum…

This study tests a new therapy called EB-HC01, which uses specially engineered natural killer (NK) immune cells to attack cancer cells that have two specific markers (HER2 and CEACAM5). The trial enrolls adults with advanced bile duct or gallbladder cancers that have worsened aft…

This early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…

This study tests whether adding immunotherapy (adebrelimab) to different chemotherapy or targeted therapy regimens can help prevent cancer recurrence in people with intrahepatic cholangiocarcinoma who have a high risk of the cancer coming back after surgery. About 90 participants…

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …

This study tests a new drug, MP0317, combined with standard chemotherapy and immunotherapy for people with advanced bile duct cancer that cannot be removed by surgery. The goal is to see if this combination helps keep the cancer from growing for at least 12 months. About 75 adult…

This early-phase study tests a new cell therapy for people with advanced biliary tract cancer (bile duct or gallbladder cancer) that has not responded to standard treatments. The therapy uses the patient's own immune T cells, enhanced with a protein called CD160 to better target …

This study tests a new approach for people with a certain type of bile duct cancer that cannot be removed by surgery. Participants first receive chemotherapy and radiation, then a liver transplant. The goal is to see if this combination helps patients live longer and stay cancer-…

This study tests two surgical techniques for bile duct cancer that has spread to nearby lymph nodes. One method removes the bile duct completely to take out all affected lymph nodes, while the other leaves the bile duct in place but may leave some lymph tissue behind. The goal is…

This study tests a type of internal radiation called high-dose-rate brachytherapy for people with liver tumors that cannot be surgically removed. The treatment uses a tiny radioactive source placed directly into the tumor to kill cancer cells while sparing nearby healthy tissue. …

This early-stage trial is testing a new mRNA-based drug called MT-304, alone or with the immunotherapy nivolumab, in adults with advanced HER2-expressing solid tumors. The main goals are to check safety, find the right dose, and get a first look at whether it shrinks tumors. Abou…

This study tests a new drug called BOLD-100 combined with standard FOLFOX chemotherapy in people with advanced colorectal, pancreatic, stomach, or bile duct cancers that have spread or cannot be removed. The goal is to see if the combination is safe and helps control tumor growth…

This early study tests a new treatment for people with stage 4 solid tumors that have stopped responding to standard care. Patients receive an injection of iron-containing nanoparticles that travel to the tumor, then a machine creates a magnetic field to heat the particles and da…

This early-phase trial is testing whether combining two targeted drugs, pemigatinib and afatinib, is safe and can shrink tumors in people with advanced solid cancers that have specific FGTR gene changes. The study includes up to 70 participants whose cancers have spread or cannot…

This early-phase trial is testing whether combining a targeted radiation treatment (Y90 radioembolization) with two immunotherapy drugs (durvalumab and tremelimumab) is safe and shows promise for people with bile duct cancer that cannot be removed by surgery. The study will enrol…

This study tests a new combination of drugs (ivosidenib, durvalumab, and chemotherapy) as a first treatment for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. The goal is to see if the combination is safe and works better than st…

This study tests a new drug, ODM-212, in about 315 adults with advanced solid tumours that cannot be cured with current treatments. The trial has two parts: first finding a safe dose, then testing that dose in more people. The main goal is to check for side effects and see how th…

This study tests a new combination of drugs for people with advanced intrahepatic cholangiocarcinoma, a type of liver cancer that cannot be removed by surgery. About 35 participants will receive an oral drug called chidamide along with standard chemotherapy and immunotherapy. The…

This phase 2 trial is testing whether combining two drugs—durvalumab (an immunotherapy) and olaparib (a targeted therapy)—can help keep advanced bile duct cancer from growing after initial chemotherapy. The study will enroll 40 adults with locally advanced or metastatic cholangio…

This phase II trial tests a combination of immunotherapy (tislelizumab), chemotherapy (gemcitabine plus cisplatin or oxaliplatin), and targeted radiation before possible surgery in 38 people with hilar cholangiocarcinoma that is borderline or not removable. The goal is to see if …

This early-stage trial tests MGC028, a drug that delivers a cancer-killing agent directly to tumor cells. About 124 adults with advanced lung, bile duct, pancreatic, or colorectal cancers that have stopped responding to standard treatments will receive the drug every three weeks.…

This phase 2 trial is testing a combination of radiation beads (Y-90), immunotherapy (durvalumab), and chemotherapy (gemcitabine and cisplatin) in 30 people with advanced bile duct cancer that cannot be removed surgically. The goal is to see if this mix can slow cancer growth and…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine and cisplatin) before and after surgery can improve outcomes for people with a type of bile duct cancer called intrahepatic cholangiocarcinoma. The trial will enroll 24 adul…

This study tests a new method to check if a liver cancer treatment called radioembolization is safe for the lungs. Currently, doctors use a test particle (MAA) to estimate lung radiation risk, but it may not be perfectly accurate. The new method uses a small 'scout dose' of the a…

This study tests whether a liver transplant after a combination of targeted internal radiation (SIRT with Yttrium-90) and chemotherapy can improve 3-year survival in people with locally advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that cannot be surgicall…

This early-phase trial tests a new drug called emavusertib added to standard chemotherapy and immunotherapy for people with untreated advanced bile duct cancer. The goal is to see if the combination is safe and to find the best dose. About 48 participants will be enrolled.

This study tests whether adding the antidepressant fluoxetine (Prozac) to standard immunotherapy can improve tumor control and survival in 240 people with advanced liver or gallbladder cancer who also have depression or anxiety. Participants will receive either fluoxetine or a pl…

This study looks at whether a liver transplant can help people with a certain type of advanced bile duct cancer that hasn't spread. Participants will first receive chemotherapy to control the cancer, then undergo a liver transplant. The goal is to see if this approach helps them …

This study tests a comprehensive fitness and nutrition program (prehabilitation) given before major cancer surgery. It includes 148 patients with pancreatic, ovarian, kidney, or bladder cancer who are frail or pre-frail. Some patients get the program alone, others get it with che…

This study tests a new first-line treatment for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer that cannot be removed by surgery. The treatment combines chemotherapy directly into the liver artery (HAIC) with two drugs: durvalumab (an immunothera…

This study tests histotripsy, a non-invasive treatment that uses focused ultrasound to destroy liver tumors without needles or surgery. It involves 40 adults with liver cancer who cannot have surgery or other standard treatments. The goal is to see if it is safe and effective at …

This phase II trial is testing a combination of two chemotherapy drugs—trifluridine/tipiracil (pills) and oxaliplatin (IV)—in people with advanced or metastatic biliary tract cancer whose first treatment stopped working. The goal is to see if this combo can control the cancer bet…

This study is testing a new way to deliver radiation therapy for liver cancer. Instead of multiple sessions over weeks, patients receive a single, high-dose treatment guided by real-time MRI scans. The approach aims to be more precise and convenient. The trial will enroll 62 adul…

This study tests two treatments for a type of bile duct cancer that cannot be surgically removed. One delivers chemotherapy directly to the liver through a pump, and the other uses tiny radioactive beads injected into the tumor's blood supply. Both are given alongside standard ch…

This study tests a pump that delivers chemotherapy directly to the liver for people with colorectal cancer or bile duct cancer that has spread to the liver. The goal is to see if the pump is safe and if patients can get their pump refilled at a local clinic instead of always trav…

This study tests a new drug called WEF-001 in people with advanced solid tumors that have a KRAS mutation, including pancreatic, colorectal, and lung cancers. The goal is to check the drug's safety and how well it shrinks tumors. About 110 adults who have already tried standard t…

This early-phase study tests a new treatment called PTC13, which uses specially engineered immune cells (CAR-T cells) to attack cancer cells that have a protein called CEA. The study includes 18 adults with advanced colorectal, stomach, pancreatic, or other solid tumors that have…

This study tests whether a procedure called endobiliary radiofrequency ablation (EB-RFA) can help people with advanced bile duct cancer live longer. EB-RFA uses a catheter to deliver heat directly to the tumor inside the bile duct. Half of the 120 participants will receive EB-RFA…

This study tests giving chemotherapy drugs (gemcitabine and oxaliplatin) directly into the liver's main artery for people with advanced bile duct cancer that hasn't spread elsewhere. The goal is to shrink tumors while reducing side effects. About 40 adults who have already tried …

This trial tests whether giving three treatments together—two medicines and a surgical patch—can lower the risk of major complications after Whipple surgery for pancreatic cancer and other tumors. The study includes 400 high-risk patients with a small pancreatic duct. If successf…

This study tests a new approach for advanced bile duct cancer, combining a precise type of radiation (PULSAR) with immunotherapy drugs and chemotherapy. The goal is to see if this combination is safe and effective. The trial is recruiting 60 adults aged 18-75 with confirmed bile …

This study is for people with advanced bile duct cancer that cannot be removed by surgery. It tests whether adding immunotherapy drugs (anti-PD-1/PD-L1 antibodies) to standard chemotherapy (gemcitabine and cisplatin) is safe and works better at shrinking tumors and delaying cance…

This study tests whether adding donor natural killer (NK) cells to standard chemotherapy can help prevent cancer from coming back after surgery for pancreatic or bile duct cancer. About 42 adults who had their tumor removed will receive either chemotherapy alone or chemotherapy p…

This early-phase study tests whether adding heat therapy and a special type of radiation to standard chemoimmunotherapy is safe and feasible for people with advanced bile duct cancer that cannot be removed by surgery. About 15 participants will receive the combination treatment. …

This study tests whether taking spirulina tablets before and after liver surgery can protect the liver and help it recover faster. Thirty adults with bile duct cancer will take either spirulina or a placebo for three weeks before and three weeks after surgery. Researchers will me…

This phase 2 trial is testing whether combining radiofrequency ablation (a heat treatment) with chemotherapy and the immunotherapy drug durvalumab can improve survival in people with advanced bile duct cancer that cannot be removed by surgery. The study will enroll 42 participant…

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety in a small group of 10 patients. It is not a cure, but …

This early-stage trial is testing a powerful mix of five chemotherapy drugs for people with advanced upper gastrointestinal cancers, including pancreatic and stomach cancers. The study uses each person's genetic profile to adjust the dose of one of the drugs (irinotecan) to try t…

This early-stage study is testing a new treatment called CEA-targeted CAR-T cells for people with advanced solid tumors like lung, stomach, colon, rectal, esophageal, or pancreatic cancer that have not responded to standard therapies. The treatment uses a patient's own immune cel…

This phase 3 trial tests whether adding a surgical glue called N-butyl-2-cyanoacrylate to standard pancreatic surgery can prevent postoperative pancreatic fistula—a common and serious leak of digestive fluids. About 194 patients with soft pancreas tissue undergoing tumor removal …

This study is testing a simple breath test to help detect gastrointestinal cancers—including cancers of the esophagus, stomach, pancreas, liver, and bowel—at an earlier stage. The test measures tiny molecules in exhaled breath that may be linked to these cancers. Participants pro…

This pilot study explores whether a combination of advanced MRI scans and a blood test called HepQuant DuO can measure liver function in people receiving radiation therapy for liver cancer. The study will enroll about 40 adults with liver cancer or liver metastases. The goal is t…

This study is developing a blood test that looks for tiny genetic molecules called miRNAs, which can signal the presence of several gastrointestinal cancers like liver, pancreatic, and colorectal cancer. Researchers will analyze blood samples from 1,000 adults—half with cancer an…

This study aims to develop a simple blood test that can tell the difference between two common types of liver cancer: hepatocellular carcinoma and cholangiocarcinoma. Researchers will analyze tiny particles called exosomes in the blood using machine learning. The goal is to help …

This study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder…

This study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…

This pilot study is testing a new radioactive tracer called 89Zr-TLX250, which targets a protein (CAIX) found on certain tumor cells. The goal is to see if PET-CT scans using this tracer can detect more tumor lesions in people with liver cancer, bile duct cancer, or neuroendocrin…

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This study tests whether a new type of PET scan using a tracer called 68Ga-FAPI-46 can more accurately detect the spread of pancreatic and bile duct cancers compared to standard CT and MRI scans. The goal is to see if this scan changes how doctors classify the cancer stage and pl…

This study looks at whether a new type of PET scan (FAPI PET/CT) can find and stage gallbladder and bile duct cancers better than the standard scan. About 60 adults with suspected or confirmed cancer will get both scans to compare accuracy. The goal is to improve detection of can…

This study tests a new PET imaging probe that targets a protein called CLDN18.2, found in some stomach, pancreatic, bile duct, and esophageal cancers. Researchers will scan 56 people (patients and healthy volunteers) to see if the scan can accurately detect tumors and guide treat…

This study aims to see if a protein test on bile fluid can accurately diagnose cholangiocarcinoma (bile duct cancer). Researchers will collect bile samples from 200 adults with bile duct narrowing during a routine scope procedure. They will compare the protein test results with s…

This study is testing a blood test that looks for DNA changes from tumors to help diagnose and manage biliary tract cancers, which are often found late and have a low survival rate. Researchers will enroll 1,800 participants with confirmed cancers to see how accurate the test is.…

This study compares giving cancer treatment at home versus in the clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves overall experience. About 220 participants will be randomly assigned to receive their reg…

This study looks at whether an improved endoscopic ultrasound (EUS) can better find cancer in lymph nodes of people with bile duct cancer. About 250 patients with presumed resectable cancer will get the enhanced EUS before surgery. The goal is to see how many patients are spared …

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This pilot study compares two ways of collecting blood to detect circulating tumor DNA (ctDNA) in people with liver or pancreatic cancers. Researchers will take blood from a standard arm vein and also from the vein that drains directly from the tumor during a biopsy. The goal is …

This study looks at how the cancer drug olutasidenib affects the way the body processes other medications. Researchers will give 16 adults with IDH1-mutated cancers a mix of test drugs before and during olutasidenib treatment to measure changes in drug levels. The goal is to ensu…

This study follows 150 adults with liver or bile duct cancer who are receiving standard treatments like surgery, ablation, or chemotherapy. Researchers will collect repeated blood samples before, during, and after treatment to analyze tumor DNA, immune cells, and proteins. The go…

This international registry collects medical images and health data from people with liver cancer or liver metastases who received a procedure called combined portal and hepatic vein embolization (PVE/HVE). The procedure blocks two sets of veins in the liver to encourage the heal…

This study tests whether people with liver cancer can be safely treated as outpatients instead of staying in the hospital after a procedure that delivers treatment directly to the liver's blood supply. About 206 patients will be randomly assigned to either outpatient or standard …

This study looks at how letting cancer patients choose which genetic results they receive affects their understanding, expectations, and satisfaction. Adults with certain cancers (cholangiocarcinoma, multiple myeloma, or early-onset colon or rectal cancer) can join. Participants …

This study tests a program where patients with liver cancer meet with a navigator who helps them connect to medical and community resources. The goal is to understand patient needs and improve access to care and research participation. Adults with hepatocellular carcinoma or othe…

This study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establis…

This study uses a special microscope called intravital microscopy to look at blood vessels inside solid tumors while patients are in surgery. Researchers want to see how these vessels work and how well they let blood and dye flow through. The goal is to learn whether tumor vessel…

This study is testing whether genetic testing of tumors and blood can help doctors choose better treatments for people with rare cancers. About 400 adults with rare solid tumors or lymphomas will have their tumors genetically analyzed. A team of experts will review the results an…

This study is collecting tissue and fluid samples from 160 people with suspected liver, bile duct, or pancreatic cancers. Researchers want to understand these cancers better and test new imaging and sampling tools for earlier, more accurate diagnosis. The study does not test a ne…

This study collects tissue and blood samples from 1,500 people with biliary tree cancers, plus healthy volunteers, to look for genetic changes and risk factors. Researchers hope to build models that predict how the cancer develops and responds to treatment. The goal is to better …

This study aims to understand why many cancer patients lose muscle and fat (cachexia), a condition that worsens their health. Researchers will use advanced techniques to analyze samples from 1000 adults with certain cancers. The goal is to find early warning signs and new targets…

This study enrolls 100 adults with advanced biliary tract cancer who are already scheduled to receive a combination of two drugs (lenvatinib and pembrolizumab). Researchers will collect blood and tumor samples to look for genetic markers that might predict who responds best to tr…

This study is looking for 500 people with certain cancers (like eye or skin melanoma, kidney cancer, or mesothelioma) and their family members to understand how common BAP1 gene mutations are. Researchers will collect medical history and questionnaires to learn about cancer risks…

This study collects bile and bile duct cells from people with Primary Sclerosing Cholangitis (PSC) and healthy volunteers to grow mini-livers called organoids. The goal is to understand how PSC progresses and leads to liver cancer. No treatment is given; it is purely for research…

This study is creating a large collection of blood, urine, stool, bile, and bile duct cells from up to 9,150 people with cholestatic liver diseases like primary biliary cholangitis and primary sclerosing cholangitis, as well as from healthy volunteers. The samples and medical dat…

This study looks back at 1,200 people who had a breathing tube placed during surgery to find out how often voice box injury happens and what makes it more likely. Researchers will check medical records and call patients to see if they had hoarseness or other throat problems after…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…